Klin Farmakol Farm. 2004;18(3):160-164

Léčba bolesti v gastroenterologii

Milan Lukáš, Martin Bortlík
Gastroenterologické centrum VFN, IV. interní klinika VFN a 1. LF UK Praha

Keywords: abdominal pain, spasmolytics, antidepresive drugs, biliary colic, esophageal spasms, irritable bowel syndrome.

Published: December 31, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lukáš M, Bortlík M. Léčba bolesti v gastroenterologii. Klin Farmakol Farm. 2004;18(3):160-164.

Základem terapie bolesti u gastrointestinálních onemocnění je podávání spazmolytik. Ze široké skupiny těchto léčiv užíváme nejčastěji spazmoanalgetika v terapii akutní bolesti způsobené spazmy trávicí trubice. U nemocných s chronickými bolestmi funkčního původu jakým je syndrom dráždivého tračníku se z výhodou užívají muskulotropní spazmolytika, tricyklická antidepresiva nebo atypická neuroleptika. Ve speciálních situacích lze využít blokátory kalciových kanálů, botulotoxin nebo nitráty. U nemocných trpících chronickými bolestmi je nezbytné zjistit prvotní příčinu, která ke vzniku bolesti vedla.

PAIN TREATMENT IN GASTROENTEROLOGY

The key of a pain treatment in gastrointestinal disorders is an administration of spasmolytics. From a broad spectrum of these drugs, spasmoanalgesics are the most frequently used in the treatment of acute pain arising from the spasms of digestive tract. Musculotropic spasmolytics, tricyclic antidepressants or atypical neuroleptics are used with a benefit in patients with chronic pain of a functional origin, such as irritative colon syndrome. Calcium channel blockers, botulotoxin and nitrates may by utilised in special situations. It is necessary to explore the primary reason provoking the pain in patients suffering from chronic pain.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Makhlouf GM. Smooth Muscle of the Gut. In: Yamada T, et al (Eds). Textbook of Gastroenterology. Lippincott Williams&Wilkins, 3rd Edition, 1999.
    2. Biancani P, Hasler WL, Weisbrodt NW. Motility of the Gut (kapitoly 9, 10, 11, 12). In: Yamada T, et al (Eds). Textbook of Gastroenterology. Lippincott Williams&Wilkins, 3rd Edition, 1999.
    3. Lukáš M. Spasmolytika a spasmoanalgetika. In: Editors: Suchopár J, Valentová Š, Buršík J Remedia Compendium, 3. vydání. Praha: Panax, 1999: 13-16.
    4. Scarpignato C, Pelosini I. Novel drugs for treatment of functional gastrointestinal disorders. In: Corazziari E. Approach to the patient with chronic gastrointestinal disorders. Milan: Messaggi, 1999: 421-471.
    5. Gelfond M, Rozen P, Keren S, Gilat T. Effect of nitrates on LOS pressure in achalasia: a potential therapeutic aid. Gut 1981; 22: 312. Go to original source... Go to PubMed...
    6. Bortolotti M, Labo G. Clinical and manometric effects of nifedipine in patients with esophageal achalasia. Gastroenterology 1981; 80: 39-44. Go to original source...
    7. Bortlík M, Lukáš M, Šimek S, et al. Bolest na hrudi jícnového původu - příčiny, diagnostika a léčebné možnosti. Čes a Slov Gastroent 1999; 53: 205-10.
    8. Coccia G, Bortolotti M, Michetti P, Dodero M. Return of esophageal peristalsis after nifedipine therapy in patients with idiopathic esophageal achalasia. Am J Gastroenterol 1992; 87: 1705-1708.
    9. Mittal RK, Holloway R, Dent J. Effect of atropine on the frequency of reflux and transient lower esophageal sphincter relaxation in normal subjects. Gastroenterology 1995; 109: 1547-1554. Go to original source... Go to PubMed...
    10. Hogan W, Sherman S, Pasricha P, Carr-Locke DL. Position paper on sphincter of Oddi manometry. Gastrointest Endosc 1997; 45: 342.
    11. Horwitz BJ, Fisher RS. The irritable bowel syndrome. N Engl J Med 2001; 344: 1846-1850. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.